Javascript must be enabled to continue!
ThP5.4 - Which Resection for Distal Cholangiocarcinoma?: Retrospective Study
View through CrossRef
Abstract
Introduction
The treatment of distal cholangiocarcinoma (DCC) is contingent upon the patient's condition and the local and lymphatic extent of the disease. Surgery remains the sole radical treatment, albeit infrequently feasible and often followed by biliary drainage. The surgical procedure involves resecting the bile duct with healthy distal and proximal margins, accompanied by lymphadenectomy. Cephalic pancreatectomy (DPC) is deemed the optimal oncological treatment for DCC.
Method
This retrospective study encompasses cancers of the main bile duct. Various factors influencing treatment were analyzed, focusing on the type of resection (biliary and pancreatic).
Results
From January 2014 to December 2021, 119 patients were treated for distal cholangiocarcinoma (88 men, 31 women, average age: 61 years). Twenty-one patients underwent endoscopic drainage, 17 transhepatic drainage, and 55 surgical interventions. Among them, 9 underwent preoperative drainage, 28 radical resection, 10 DPC, 18 biliary resections, and one total pancreatectomy. In 27 patients, radical surgery was impossible; 20 underwent drainage, and 7 did not. Three early surgical revisions in the biliary resection group, with incidents of digestive hemorrhage and hemoperitoneum. Two moderate pancreatic fistulas and immediate postoperative hypoglycemia were recorded. Two deaths in the biliary resection group and 7 in-hospital deaths in the biliary drainage group. All patients with external drainage died before 12 months, while 8 patients from the endoscopic drainage group survived after 12 months. Patients with radical surgery and adjuvant treatment exhibited longer survivals (36 months vs. 45 months).
Conclusion
Improving the prognosis of DCC requires early diagnosis and radical surgery combined with adjuvant treatment.
Title: ThP5.4 - Which Resection for Distal Cholangiocarcinoma?: Retrospective Study
Description:
Abstract
Introduction
The treatment of distal cholangiocarcinoma (DCC) is contingent upon the patient's condition and the local and lymphatic extent of the disease.
Surgery remains the sole radical treatment, albeit infrequently feasible and often followed by biliary drainage.
The surgical procedure involves resecting the bile duct with healthy distal and proximal margins, accompanied by lymphadenectomy.
Cephalic pancreatectomy (DPC) is deemed the optimal oncological treatment for DCC.
Method
This retrospective study encompasses cancers of the main bile duct.
Various factors influencing treatment were analyzed, focusing on the type of resection (biliary and pancreatic).
Results
From January 2014 to December 2021, 119 patients were treated for distal cholangiocarcinoma (88 men, 31 women, average age: 61 years).
Twenty-one patients underwent endoscopic drainage, 17 transhepatic drainage, and 55 surgical interventions.
Among them, 9 underwent preoperative drainage, 28 radical resection, 10 DPC, 18 biliary resections, and one total pancreatectomy.
In 27 patients, radical surgery was impossible; 20 underwent drainage, and 7 did not.
Three early surgical revisions in the biliary resection group, with incidents of digestive hemorrhage and hemoperitoneum.
Two moderate pancreatic fistulas and immediate postoperative hypoglycemia were recorded.
Two deaths in the biliary resection group and 7 in-hospital deaths in the biliary drainage group.
All patients with external drainage died before 12 months, while 8 patients from the endoscopic drainage group survived after 12 months.
Patients with radical surgery and adjuvant treatment exhibited longer survivals (36 months vs.
45 months).
Conclusion
Improving the prognosis of DCC requires early diagnosis and radical surgery combined with adjuvant treatment.
Related Results
Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker
Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker
Abstract
Background
Distal cholangiocarcinoma is an aggressive malignancy with a dismal prognosis. Diagnostic and prognostic biomarkers for distal c...
Risk Factors for Anorectal Dysfunction After Interspincteric Resection in Patients With Low Rectal Cancer
Risk Factors for Anorectal Dysfunction After Interspincteric Resection in Patients With Low Rectal Cancer
Purpose: The objective of this study was to explore the risk factors for anorectal dysfunction after intersphincteric resection in patients with low rectal cancer.Methods: A total ...
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma Aims: The c‐erbB‐2 and c‐Met proto‐oncogenes are important for ...
The diagnosis and treatment of cholangiocarcinoma
The diagnosis and treatment of cholangiocarcinoma
Background: Cholangiocarcinoma (CCA) is the second most common primary hepatic tumor. In recent years, its prognosis has improved because of wide resections and the establishment o...
Abstract 1400: C1GALT1 regulates malignant phenotypes of cholangiocarcinoma cells
Abstract 1400: C1GALT1 regulates malignant phenotypes of cholangiocarcinoma cells
Abstract
Identifying molecular targets for cholangiocarcinoma is an urgent need to overcome the treatment failure and death from cancer cell invasion and metastasis....
Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
ABSTRACTIntroductionThe mainstay treatment for intrahepatic cholangiocarcinoma is surgical resection, the impact of lymph node dissection and the scope of lymph node dissection for...
Aberrant DNA Methylation in Cholangiocarcinoma
Aberrant DNA Methylation in Cholangiocarcinoma
Cholangiocarcinoma is an epithelial malignancy arising in the region between the intrahepatic bile ducts and the ampulla of Vater at the distal end of the common bile duct. The eff...
Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report
Multimodal treatment of an advanced intrahepatic cholangiocarcinoma and its recurrence – a case report
Introduction: Intrahepatic cholangiocarcinoma (ICC) is rare and often diagnosed in an advanced stage. Neoadjuvant therapy is not established and data on its value are in palliative...

